In particular, the use of the PPARγ agonist rosiglitazone in a lithium–pilocarpine model of TLE was found to prevent cognitive impairment, increase antioxidant superoxide dismutase activity in brain cells [83], and reduce the inflammatory response of microglia [84]. The gene discussed is PPARG; the disease is Cognitive impairment.